85% of physicians: Fear of malpractice leads to over-treatment

Over-treating patients means wasted resources and increased exposure to harm for individuals. In a study published in PLOS ONE, researchers surveyed physicians on causes, prevalence and consequences of over-treatment.

This study evaluated survey responses of 2,106 physicians from the American Medical Association (AMA) masterfile. The survey asked respondents about the extent of over-treatment and the causes, solutions and implications of care.

Overall, 70.1 percent of those surveyed responded. Results showed physicians reported 20.6 percent of medical care was unnecessary including 22 percent of prescriptions, 24.9 percent of testing and 11.1 percent of procedures. The top reason for over-treatment was fear of malpractice at 84.7 percent, patient pressure at 59 percent and difficulty accessing medical records at 38.2 percent. Popular solutions included training residents at 55.2 percent, easier access to outside health records at 52 percent and more practice guidelines at 51.5 percent.

“From the physician perspective, over-treatment is common,” concluded first author Heather Lyu and colleagues. “Efforts to address the problem should consider the causes and solutions offered by physicians.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.